The immune checkpoints CTLA-4 and PD-1/PD-L1 axis are currently central targets of cancer immunotherapy, where checkpoint inhibitors have revolutionized treatment by enhancing anti-tumor T-cell responses [49]. This evidence concerns the gene CTLA4 and cancer.